Bavarian Nordic

Q1 2021

Spreading hope,
pioneering vaccines

27 May 2021

BAVARIAN NORDIC

Disclaimer

This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements regarding our short-term objectives and opportunities, financial expectations for the full year and financial preparedness as of year end, as well as statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Bavarian Nordic – a fully integrated vaccine company

By 2025, we aspire to be one of the largest pure play vaccine companies improving and saving lives by excelling in ***R&D innovation, manufacturing and commercialization***

700+
employees



4
marketed products: rabies, TBE, smallpox, Ebola

Commercial scale manufacturing facility with inhouse fill and finish being added during 2021

Commercial infrastructure supporting key markets in US and EU

RSV
late-stage vaccine candidate in blockbuster indication

COVID-19
advancing clinical development

Profitable vaccine business

“Immunisation is one of the best buys in global health and has a crucial role in achieving 14 of the 17 SDGs.

- Gavi, the Vaccine Alliance

Highlights YTD

Business performance

- Rabies market remains heavily impacted by COVID-19
- TBE show signs of stability.
- Smallpox contracts driving larger revenues in Q1.
- Raised DKK 1.1 billion through a private placement
- Full-year guidance maintained

Expanding German portfolio through marketing and distribution agreement with Dynavax on HEPLISAV-B.

Smallpox vaccine

Supply orders totalling DKK 90m from three European countries – delivered and invoiced during Q1.

New USD 31m order from the Public Health Agency of Canada for delivery in 2022 and 2023.

USG exercise of USD 12m option for additional doses of liquid-frozen JYNNEOS®

Ebola

New USD 28m supply order from Janssen for delivery in 2021.

WHO prequalification of J&J vaccine regimen provides broader access in countries at risk.

COVID-19

Encouraging preclinical results demonstrated high levels of neutralizing antibodies, resulting in complete protection from SARS-CoV-2, including potential for broad protection against variants.

BN to fund a phase 2 clinical study and scale-up of manufacturing to accommodate potential future clinical development to support licensure of the COVID-19 vaccine.

RSV

Human challenge trial initiated – results anticipated in 2H 2021.

Expanding commercial footprint in Germany

Marketing & distribution agreement with Dynavax on HEPLISAV-B in Germany

- First EU country to launch two-dose hepatitis-B vaccine (Q4 2021)
- Will break monopoly in largest EU market, currently around EUR 27m annually
- Strong overlap with existing BN target audience
  - General practitioners, occupational health groups and travel medicine specialists
- Complementing BN's vaccine portfolio and takes advantage of dedicated sales force



HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted)

- FDA approved in 2017, EC approved in February 2021
- Indicated for active immunization against hepatitis B virus infection (HBV) caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
- Only FDA- and EC-approved hepatitis B vaccine with a two-dose schedule for adults that is completed in one month.

A need for continued advances in COVID-19 vaccine development

Durability and breadth of protection for existing COVID-19 vaccines against new circulating variants is sub-optimal/remains unknown.

Unlikely that COVID-19 can be eliminated and regular booster vaccinations and/or new COVID vaccines will likely be required to reduce the continuing burden of disease in the worldwide population.

The requirement for billions of COVID-19 vaccine doses has highlighted the complexity and a number of bottlenecks in vaccine production and supply

Adeno platform unlikely to be suitable for revaccination & emerging booster data with mRNA vaccines show marked increase in systemic Adverse Events (AEs including grade 3)



Accelerating the development of a next-generation COVID-19 vaccine

- Our COVID-19 vaccine candidate, **ABNCoV2**, has shown to be highly immunogenic in relevant preclinical models inducing durable and superior responses to convalescent sera from patients that have recovered from COVID-19.
- Coupled with the ease of production and the ability to rapidly adapt the vaccine platform to new potentially more deadly variants, ABNCoV2 looks like a highly promising candidate.
- Bavarian Nordic will sponsor a phase 2 clinical trial and scale-up manufacturing in preparation for Phase 3 (pending external funding)



ABNCoV2 preclinical data

Preclinical data show high levels of neutralizing antibodies - also against emerging variants - and protection against SARS-CoV2 challenge.

Neutralizing antibodies & protection

- Two doses of non-adjuvanted ABNCoV2 led to >50-fold higher titers than human convalescent sera and complete protection from SARS-CoV-2.
- With a GMT ratio of vaccine vs. convalescent sera ≥ 1 vaccine efficacy has been reported above 80% for other vaccines[1].



Broad neutralizing responses against variants

- Pfizer BioNTech vaccine reported a 2.7 fold lower neutralizing titer in people against the South African variant
- Similar results have been reported for Moderna vaccine in mice
- Janssen vaccine demonstrated a 72% efficacy in USA (mainly Wuhan strain) and a 57% efficacy in South Africa



1. Earle et al. MedRxiv, March 2021, https://doi.org/10.1101/2021.03.17.20200246)

ABNCoV2 clinical development

- **Phase 1** on-going – initial data available in June/July
  - Preliminary data indicate that the vaccine is well tolerated and induces high levels of neutralizing antibodies
- **Phase 2** to be initiated in June 2021, with initial immunogenicity data August

Phase 2 design

Multi-center study in Germany and the Netherlands to evaluate the potential of ABNCoV2 to boost existing immunity

GROUP 1

Seronegative | N = 100 | *Booster vaccination 28 days after prime*

GROUP 2

Seropositive | N = 150 | *One-shot booster vaccination*

Previously infected or vaccinated

RSV – de-risking Phase 3 with planned human challenge trial

- Human challenge trial in 2021 will provide efficacy insights ahead of Phase 3
- Postponing Phase 3 study initiation by one year into 2022 due to anticipated COVID-19 impact

Human challenge trial

- Assessing the effect of vaccination with MVA-BN-RSV vaccine, in reducing the RSV viral loads due to the challenge strain when compared to placebo
- Other predefined outcome measures, such as symptoms scores will also be evaluated

Phase 3 in older adults

- Randomized, placebo-controlled trial with an adaptive design enrolling 12,000 - 14,000 subjects over two seasons (6,000 for the first season, 6,000-8,000 for the second season)
- After passing the first season threshold there would be a ~75% chance of successfully reaching the efficacy endpoint of the trial
- Estimated costs to determine futility after the first season will be USD 40m. Second season will cost an additional USD 50-70m



Creating a center of excellence for vaccine manufacturing

Fill and finish

Construction completed

Validation & qualification completed

Ready for first commercial manufacturing in 2021

Bulk manufacturing

Construction work ongoing for expansion of facility to allow for simultaneous bulk manufacturing of multiple products

Current bulk facility shut-down from 3Q21 to 2Q22 due to rebuild

Rabies vaccine market development and performance

Rabies market





Both post-exposure and pre-exposure segments impacted by US lock-down and lack of domestic and international travel.

However, the market remains more resilient than the European market.

Pre-exposure market eroded during Q2 2020 and continues to suffer from COVID-19 travel restrictions

Data source: IQVIA

Rabipur/RabAvert sales (mDKK)

Q1 2021	Q1 2020	Growth
80	218	-63%

- COVID-19 impact on key markets
- Strong Q1 2020 due to inventory build-up and competitor out-of-stock



TBE vaccine market development and performance

TBE market



Total market down in Q1 vs. prior year, but Germany breaking the trend with 8% increase in Q1 2021 vs. Q1 2020

Underlying demand for TBE vaccination remains, but market still impacted by COVID-19 due to limited access to physicians (either forced or voluntarily).

Data source: IQVIA

Encepur sales (mDKK)

Q1 2021	Q1 2020	Growth
98	103	-5%

- Decline caused by wholesaler inventory movements
- Positive growth in German market, but total market still down
- Encepur market share gain of 0.2 p.p. in Germany



Profit & Loss

mDKK	Q1 2021	Q1 2020
Revenue	535	365
Production costs	377	243
Gross profit	**158**	122
Research and development costs	122	66
SG&A costs	124	126
Total operating costs	**246**	192
Other operating income		628
EBIT	**(88)**	556
Net financial items	(42)	(42)
EBT	**(130)**	516
Tax	1	1
Net profit for the period	**(131)**	515
EBITDA	**1**	641

Revenue was DKK 535 million, with increase driven by sale of smallpox vaccine.

Gross profit impacted by residual manufacturing cost from manufacture of RSV clinical trial material not allocated to R&D.

R&D costs increased, primarily driven by manufacturing of RSV phase 3 material and activities related to support technology transfer of Rabipur/RabAvert and Encepur.

SG&A- higher administrative costs due to ongoing transfer project for Rabipur/RabAvert and Encepur and the impact from the extension of the executive management during 2020 partly offset by lower distribution costs.

EBITDA was DKK 1 million. In 2020, EBITDA was positively impacted by the sale of Priority Review Voucher

Revenue Q1 2021
DKK million



Cash flow and Balance Sheet

Selected cash flow figures

mDKK	Q1 2021	Q1 2020
Cash flow from operating activities	(120)	432
Cash flow from investment activities	(1,069)	(630)
Free cash flow	**(1,189)**	(198)
Cash flow from financing activities	1,146	1,363
Net cash flow for the period	**(43)**	1,165

Cash flow from operating activities was negative by DKK 120 million (positive by DKK 432 million), primarily due to the negative Net profit for the period.

Cash flow from investment activities was negative by DKK 1,069 million (negative by DKK 630 million) following net investments in securities of DKK 973 million (net investment of DKK 573 million). Cash flow from investment activities also include DKK 81 million (DKK 23 million) of investments in property, plant and equipment related to the ongoing expansion of the bulk facility for future production of Rabipur/RabAvert and Encepur. Investment in intangible assets amounted to DKK 15 million and includes the ongoing Rabipur/RabAvert and Encepur technology transfer project and IT system investments.

Cash flow from financing activities was a contribution of DKK 1,146 million (DKK 1,363 million), following the proceeds from capital increase through private placement.

Selected balance sheet figures

mDKK	Mar-31 2021	Mar-31 2020
Intangible assets	5,235	5,424
Total assets	9,748	9,005
Equity	5,921	5,111
Non-current liabilities	2,378	3,185
Current liabilities	1,450	710
Securities, cash and cash equivalents	2,589	2,205
Debt, bank & institutional	(395)	(397)
Net cash*	2,194	1,808

Increase in **equity** largely attributed to the capital increase through a private placement in March 2021, which increased the equity by DKK 1,148 million before costs.

*Deferred consideration to GSK of DKK 2,849 million not included. Book value of the deferred consideration is calculated using NPV and probability weighted milestone payments. Unutilized credit facilities of DKK 244 million not included either.

2021 Outlook

2021 guidance

mDKK	FYE 2021
Revenue	**1,900 - 2,200**
EBITDA	**100 - 250**
Cash position (securities, cash and cash equivalents)	**1,400 - 1,600**

The guidance intervals reflects the current uncertainty related to COVID-19.

The low end of the **revenue and EBITDA** range reflects a scenario where a lockdown due to COVID-19 continues beyond Q1 in key markets like the US and Germany.

The higher end of the **revenue and EBITDA** range reflects a scenario where a gradual reopening will happen in key markets during Q2 and where travel starts picking up again in Q3 and Q4 of 2021.

The smallpox and Ebola business are not expected to be impacted by COVID-19.

R&D spend of approximately DKK 750 million, whereof up to DKK 200 million will be capitalized (ABNCoV2).

Cash at year-end impacted by:
- Investment of approximately DKK 650 million in facility expansion and tech-transfer from GSK
- Working capital increases of approximately DKK 300 million (inventories)
- Continued milestone payments to GSK
- Draw-down of EUR 30 million existing credit facility with European Investment Bank

2021 activities and milestones

R&D
- Initiate and complete a Phase 2 human challenge trial in RSV
- Continue preparations for initiation of the Phase 3 trial of MVA-BN RSV in older adults in 2022
- Advance the development of the COVID-19 vaccine candidate, ABNCoV2 into Phase 2 and scale-up of manufacturing to phase 3 volume levels
- Advance the development of smallpox MVA-BN freeze-dried formulation
- Further explore intravenous administration of brachyury containing construct within immunotherapy.

Commercial
- Drive profitable growth for Rabipur/RabAvert and Encepur
- Take over physical distribution for Rabipur/RabAvert and Encepur in remaining markets
- Improve awareness and image of Bavarian Nordic with key stakeholders

Manufacturing
- Filling of first commercial vaccine doses in the newly built fill and finish facility
- Completion of construction of new/amended drug substance facility
- Progress the manufacturing technology transfer of Rabipur/RabAvert and Encepur according to plan, including completing qualification of packaging performed at a selected contract manufacturer


Q&A